NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Funding for NIAMS Clinical Trial Implementation with simplified review changes; open for UG3/UH3 clinical trials under this Cooperative Agreement.
Funder: National Institutes of Health
Due Dates: March 4, 2025 | July 2, 2025 | November 4, 2025 | March 4, 2026 | July 2, 2026 | November 2, 2026 | March 4, 2027 (new, renewal, resubmission, revision)
Funding Amounts: UG3 phase: up to $250,000 direct costs (1 year); UH3 phase: no set limit, up to 5 years; total project period up to 6 years
Summary: Supports implementation of investigator-initiated, single or multi-site interventional clinical trials (all phases) in NIAMS mission areas using a milestone-driven UG3/UH3 cooperative agreement.
Key Information: Application review uses the new NIH simplified review framework; consultation with NIAMS staff before applying is strongly encouraged.
Description
This opportunity from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at NIH supports the implementation of investigator-initiated, single or multi-site, interventional clinical trials (all phases) relevant to arthritis, musculoskeletal, or skin diseases. The funding mechanism is a two-phase, milestone-driven cooperative agreement (UG3/UH3):
- UG3 phase (up to 1 year): Supports final trial preparations (e.g., establishing single IRB, site contracts, staff hiring, protocol finalization).
- UH3 phase (up to 5 years): Supports full trial implementation, including participant enrollment, data collection, and analysis.
Transition from UG3 to UH3 is contingent on meeting pre-specified milestones. The program is designed for trials that are ready to begin implementation, with all major planning and design work already completed.
This re-issue incorporates the NIH's new simplified review criteria for research project grant applications.
